Transgender health and the impact of aging and menopause

References

• Spizzirri G, Eufrásio R, Lima MCP, et al. Proportion of people identified as transgender and non-binary gender in Brazil. Sci Rep. 2021;11(1):2240.
   PubMed Web of Science ®Google Scholar
• Crissman HP, Berger MB, Graham LF, et al. Transgender demographics: a household probability sample of US adults, 2014. Am J Public Health. 2017;107(2):213–215.
   PubMed Web of Science ®Google Scholar
• Kuyper L, Wijsen C. Gender identities and gender dysphoria in the Netherlands. Arch Sex Behav. 2014;43(2):377–385.
   PubMed Web of Science ®Google Scholar
• Van Caenegem E, Wierckx K, Elaut E, et al. Prevalence of gender nonconformity in Flanders, Belgium. Arch Sex Behav. 2015;44(5):1281–1287.
   PubMed Web of Science ®Google Scholar
• Åhs JW, Dhejne C, Magnusson C, et al. Proportion of adults in the general population of Stockholm County who want gender-affirming medical treatment. PLoS One. 2018;13(10):e0204606.
   PubMed Web of Science ®Google Scholar
• Clark TC, Lucassen MF, Bullen P, et al. The health and well-being of transgender high school students: results from the New Zealand adolescent health survey (Youth’12). J Adolesc Health. 2014;55(1):93–99.
   PubMed Web of Science ®Google Scholar
• Foster Skewis L, Bretherton I, Leemaqz SY, et al. Short-term effects of gender-affirming hormone therapy on dysphoria and quality of life in transgender individuals: a prospective controlled study. Front Endocrinol (Lausanne). 2021;12:717766.
   PubMed Web of Science ®Google Scholar
• van Leerdam TR, Zajac JD, Cheung AS. The effect of gender-affirming hormones on gender dysphoria, quality of life, and psychological functioning in transgender individuals: a systematic review. Transgender Health. 2023;8(1):6–21.
   PubMedGoogle Scholar
• Baker KE, Wilson LM, Sharma R, et al. Hormone therapy, mental health, and quality of life among transgender people: a systematic review. J Endocr Soc. 2021;5(4):bvab011.
   PubMed Web of Science ®Google Scholar
• Javier C, Crimston CR, Barlow FK. Surgical satisfaction and quality of life outcomes reported by transgender men and women at least one year post gender-affirming surgery: a systematic literature review. Int J Transgend Health. 2022;23(3):255–273.
   PubMed Web of Science ®Google Scholar
• Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Trans Health. 2022;23(sup1):S1–S259.
   PubMedGoogle Scholar
• Safer JD, Coleman E, Feldman J, et al. Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):168–171.
   PubMed Web of Science ®Google Scholar
• Ortiz-Martínez Y, Ríos-González CM. Need for more research on and health interventions for transgender people. Sex Health. 2017;14(2):196–197.
   PubMed Web of Science ®Google Scholar
• Safer JD. Research gaps in medical treatment of transgender/nonbinary people. J Clin Invest. 2021;131(4):e142029.
   PubMed Web of Science ®Google Scholar
• Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health. 2013;103(5):943–951.
   PubMed Web of Science ®Google Scholar
• Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull. 2003;129(5):674–697.
   PubMed Web of Science ®Google Scholar
• Scandurra C, Amodeo AL, Valerio P, et al. Minority stress, resilience, and mental health: a study of italian transgender people. J Soc Issues. 2017;73(3):563–585.
   Web of Science ®Google Scholar
• Hughes L, Shireman TI, Hughto J. Privately insured transgender people are at elevated risk for chronic conditions compared with cisgender counterparts. Health Aff (Millwood). 2021;40(9):1440–1448.
   PubMedGoogle Scholar
• Dragon CN, Guerino P, Ewald E, et al. Transgender medicare beneficiaries and chronic conditions: exploring fee-for-service claims data. LGBT Health. 2017;4(6):404–411.
   PubMed Web of Science ®Google Scholar
• Bretherton I, Thrower E, Zwickl S, et al. The health and well-being of transgender Australians: a national community survey. LGBT Health. 2021;8(1):42–49.
   PubMed Web of Science ®Google Scholar
• Zwickl S, Wong AFQ, Dowers E, et al. Factors associated with suicide attempts among Australian transgender adults. BMC Psychiatry. 2021;21(1):81.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhu X, Wright L, et al. Suicidal ideation and attempted suicide amongst Chinese transgender persons: national population study. J Affect Disord. 2019;245:1126–1134.
   PubMed Web of Science ®Google Scholar
• Budhwani H, Hearld KR, Milner AN, et al. Transgender women’s experiences with stigma, trauma, and attempted suicide in the Dominican Republic. Suicide Life Threat Behav. 2018;48(6):788–796.
   PubMed Web of Science ®Google Scholar
• Marshall E, Claes L, Bouman WP, et al. Non-suicidal self-injury and suicidality in trans people: a systematic review of the literature. Int Rev Psychiatry. 2016;28(1):58–69.
   PubMed Web of Science ®Google Scholar
• Boyer TL, Youk AO, Haas AP, et al. Suicide, homicide, and all-cause mortality among transgender and cisgender patients in the veterans health administration. LGBT Health. 2021;8(3):173–180.
   PubMed Web of Science ®Google Scholar
• Hughes LD, King WM, Gamarel KE, et al. Differences in all-cause mortality among transgender and Non-Transgender people enrolled in private insurance. Demography. 2022;59(3):1023–1043.
   PubMedGoogle Scholar
• Hughes LD, King WM, Gamarel KE, et al. US Black-White differences in mortality risk among transgender and cisgender people in private insurance, 2011–2019. Am J Public Health. 2022;112(10):1507–1514.
   PubMed Web of Science ®Google Scholar
• Wiepjes CM, den Heijer M, Bremmer MA, et al. Trends in suicide death risk in transgender people: results from the Amsterdam cohort of gender dysphoria study (1972–2017). Acta Psychiatr Scand. 2020;141(6):486–491.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International classification of diseases eleventh revision (ICD-11). Geneva: World Health Organization; 2022.
   Google Scholar
• Cheung AS, Wynne K, Erasmus J, et al. Position statement on the hormonal management of adult transgender and gender diverse individuals. Med J Aust. 2019;211(3):127–133.
   PubMed Web of Science ®Google Scholar
• Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903.
   PubMed Web of Science ®Google Scholar
• Cheung AS, Leemaqz SY, Wong JWP, et al. Non-binary and binary gender identity in Australian trans and gender diverse individuals. Arch Sex Behav. 2020;49(7):2673–2681.
   PubMed Web of Science ®Google Scholar
• Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019;139(11):1461–1462.
   PubMed Web of Science ®Google Scholar
• Angus L, Leemaqz S, Ooi O, et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect. 2019;8(7):935–940.
   PubMed Web of Science ®Google Scholar
• Angus LM, Nolan BJ, Zajac JD, et al. A systematic review of anti-androgens and feminisation in transgender women. Clin Endocrinol (Oxf). 2021;94:743–752.
   PubMed Web of Science ®Google Scholar
• Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169(4):205–213.
   PubMed Web of Science ®Google Scholar
• Ettner R. Care of the elderly transgender patient. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):580–584.
   PubMedGoogle Scholar
• Adan M, Scribani M, Tallman N, et al. Worry and wisdom: a qualitative study of transgender elders’ perspectives on aging. Transgender Health. 2021;6(6):332–342.
   PubMedGoogle Scholar
• Guo Y, Li Q, Yang X, et al. Prevalence of alzheimer’s and related dementia diseases and risk factors among transgender adults, Florida, 2012–2020. Am J Public Health. 2022;112(5):754–757.
   PubMed Web of Science ®Google Scholar
• van Heesewijk JO, Dreijerink KMA, Wiepjes CM, et al. Long-term gender-affirming hormone therapy and cognitive functioning in older transgender women compared with cisgender women and men. J Sex Med. 2021;18(8):1434–1443.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Hunter MS. Transgender women’s experiences and beliefs about hormone therapy through and beyond mid-age: an exploratory UK study. Int J Transgend. 2019;20(1):98–107.
   PubMedGoogle Scholar
• Cai X, Hughto JMW, Reisner SL, et al. Benefit of gender-affirming medical treatment for transgender elders: later-Life alignment of mind and body. LGBT Health. 2019;6(1):34–39.
   PubMed Web of Science ®Google Scholar
• Balcerek MI, Nolan BJ, Brownhill A, et al. Feminizing hormone therapy prescription patterns and cardiovascular risk factors in aging transgender individuals in Australia. Front Endocrinol (Lausanne). 2021;12:667403.
   PubMed Web of Science ®Google Scholar
• Dekker MJ, Wierckx K, Van Caenegem E, et al. A European network for the investigation of gender incongruence: endocrine part. J Sex Med. 2016;13(6):994–999.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22(2):201–210.
   PubMed Web of Science ®Google Scholar
• Ott J, Kaufmann U, Bentz EK, et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93(4):1267–1272.
   PubMed Web of Science ®Google Scholar
• van Kesteren PJ, Asscheman H, Megens JA, et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–342.
   PubMed Web of Science ®Google Scholar
• Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471–478.
   PubMed Web of Science ®Google Scholar
• Lim HY, Leemaqz SY, Torkamani N, et al. Global coagulation assays in transgender women on oral and transdermal estradiol therapy. J Clin Endocrinol Metab. 2020;105(7):dgaa262.
   PubMed Web of Science ®Google Scholar
• Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010;8(8):1736–1744.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738.
   PubMed Web of Science ®Google Scholar
• Kozato A, Fox GWC, Yong PC, et al. No venous thromboembolism increase among transgender female patients remaining on estrogen for gender-affirming surgery. J Clin Endocrinol Metab. 2021;106(4):e1586–e1590.
   PubMed Web of Science ®Google Scholar
• Boskey ER, Taghinia AH, Ganor O. Association of surgical risk with exogenous hormone use in transgender patients: a systematic review. JAMA Surg. 2019;154(2):159–169.
   PubMed Web of Science ®Google Scholar
• Haveles CS, Wang MM, Arjun A, et al. Effect of cross-sex hormone therapy on venous thromboembolism risk in male-to-female gender-affirming surgery. Ann Plast Surg. 2021;86(1):109–114.
   PubMed Web of Science ®Google Scholar
• Nolan BJ, Cheung AS. Estradiol therapy in the perioperative period: implications for transgender people undergoing feminizing hormone therapy. Yale J Biol Med. 2020;93(4):539–548.
   PubMed Web of Science ®Google Scholar
• Arrington-Sanders R, Connell NT, Coon D, et al. Assessing and addressing the risk of venous thromboembolism across the spectrum of gender affirming care: a review. Endocr Pract. 2022 Dec 17;S1530-891X(22)00898-9. DOI:10.1016/j.eprac.2022.12.008
   Google Scholar
• Defreyne J, Van de Bruaene LDL, Rietzschel E, et al. Effects of Gender-Affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. Clin Chem. 2019;65(1):119–134.
   PubMed Web of Science ®Google Scholar
• Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641–2651.
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol. 2014;170(6):809–819.
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25.
   PubMed Web of Science ®Google Scholar
• Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005597.
   PubMed Web of Science ®Google Scholar
• Caceres BA, Jackman KB, Edmondson D, et al. Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014–2017 BRFSS. J Behav Med. 2020;43(2):329–338.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Rubin KH, Petersen TG, et al. Cardiovascular risk in Danish transgender persons: a matched historical cohort study. Eur J Endocrinol. 2022;187(3):463–477.
   PubMed Web of Science ®Google Scholar
• Karalexi MA, Frisell T, Cnattingius S, et al. Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. Eur J Prev Cardiol. 2022;29(15):2017–2026.
   PubMed Web of Science ®Google Scholar
• Luria MH, Johnson MW, Pego R, et al. Relationship between sex hormones, myocardial infarction, and occlusive coronary disease. Arch Intern Med. 1982;142(1):42–44.
   PubMedGoogle Scholar
• Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007;68(8):563–568.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, Urologic Diseases in America Project, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–1500.
   PubMed Web of Science ®Google Scholar
• Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–1524.
   PubMedGoogle Scholar
• Gulanski BI, Flannery CA, Peter PR, et al. Compromised endothelial function in transgender men taking testosterone. Clin Endocrinol (Oxf). 2020;92(2):138–144.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wang R, Barrett BW, et al. Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus. AIDS. 2022;36(13):1801–1809.
   PubMed Web of Science ®Google Scholar
• Schutte MH, Kleemann R, Nota NM, et al. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS ONE. 2022;17(3):e0261312.
   PubMed Web of Science ®Google Scholar
• Cocchetti C, Castellini G, Iacuaniello D, et al. Does gender-affirming hormonal treatment affect 30-Year cardiovascular risk in transgender persons? A two-year prospective european study (ENIGI). J Sex Med. 2021;18(4):821–829.
   PubMed Web of Science ®Google Scholar
• Aranda G, Mora M, Hanzu FA, et al. Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy. Endocrinol Diabetes Nutr (Engl Ed). 2019;66(6):385–392.
   PubMed Web of Science ®Google Scholar
• Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3914–3923.
   PubMed Web of Science ®Google Scholar
• Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology. 2018;6(3):446–454.
   PubMed Web of Science ®Google Scholar
• Sorlie PD, Garcia-Palmieri MR, Costas R Jr, et al. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Am Heart J. 1981;101(4):456–461.
   PubMed Web of Science ®Google Scholar
• Gagnon DR, Zhang TJ, Brand FN, et al. Hematocrit and the risk of cardiovascular disease–the Framingham study: a 34-year follow-up. Am Heart J. 1994;127(3):674–682.
   PubMed Web of Science ®Google Scholar
• Paul L, Jeemon P, Hewitt J, et al. Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults. Hypertension. 2012;60(3):631–638.
   PubMed Web of Science ®Google Scholar
• Braekkan SK, Mathiesen EB, Njolstad I, et al. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica. 2010;95(2):270–275.
   PubMed Web of Science ®Google Scholar
• Poteat TC, Divsalar S, Streed CG Jr, et al. Cardiovascular disease in a population-based sample of transgender and cisgender adults. Am J Prev Med. 2021;61(6):804–811.
   PubMed Web of Science ®Google Scholar
• Streed CG Jr, Beach LB, Caceres BA, et al. Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association. Circulation. 2021;144(6):e136–e148.
   PubMed Web of Science ®Google Scholar
• Wiepjes CM, de Blok CJ, Staphorsius AS, et al. Fracture risk in trans women and trans men using long-term gender-affirming hormonal treatment: a nationwide cohort study. J Bone Miner Res. 2020;35(1):64–70.
   PubMed Web of Science ®Google Scholar
• Bretherton I, Ghasem-Zadeh A, Leemaqz SY, et al. Bone microarchitecture in transgender adults: a cross-sectional study. J Bone Miner Res. 2022;37(4):643–648.
   PubMed Web of Science ®Google Scholar
• Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92–97.
   PubMed Web of Science ®Google Scholar
• Wiepjes CM, de Jongh RT, de Blok CJ, et al. Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen. J Bone Miner Res. 2019;34(3):447–454.
   PubMed Web of Science ®Google Scholar
• Vlot MC, Wiepjes CM, de Jongh RT, et al. Gender-affirming hormone treatment decreases bone turnover in transwomen and older transmen. J Bone Miner Res. 2019;34(10):1862–1872.
   PubMed Web of Science ®Google Scholar
• Zwickl S, Burchill L, Wong AFQ, et al. Pelvic pain in transgender people using testosterone therapy. LGBT Health. 2023 Jan 4. DOI:10.1089/lgbt.2022.0187
   Web of Science ®Google Scholar
• Grimstad FW, Boskey E, Grey M. New-Onset abdominopelvic pain after initiation of testosterone therapy among trans-masculine persons: a Community-Based exploratory survey. LGBT Health. 2020;7(5):248–253.
   PubMed Web of Science ®Google Scholar
• Moussaoui D, Elder CV, O’Connell MA, et al. Pelvic pain in transmasculine adolescents receiving testosterone therapy. Int J Trans Health. 2022;1–9. DOI:10.1080/26895269.2022.2147118
   Google Scholar
• Defreyne J, Vanwonterghem Y, Collet S, et al. Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: a prospective cohort study (ENIGI). Int J Transgend Health. 2020;21(2):163–175.
   PubMedGoogle Scholar
• Grimstad F, Kremen J, Shim J, et al. Breakthrough bleeding in transgender and gender diverse adolescents and young adults on long-term testosterone. J Pediatr Adolesc Gynecol. 2021;34(5):706–716.
   PubMed Web of Science ®Google Scholar
• Barnas JL, Pierpaoli S, Ladd P, et al. The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU Int. 2004;94(4):603–605.
   PubMed Web of Science ®Google Scholar
• Yong PJ. Clinical conundrum: a 33-year-old with pain post-orgasm and a history of endometriosis. J Obstet Gynaecol Can. 2020;42(5):625–628.
   PubMed Web of Science ®Google Scholar
• Ho MH, Bhatia NN, Bhasin S. Anabolic effects of androgens on muscles of female pelvic floor and lower urinary tract. Curr Opin Obstet Gynecol. 2004;16(5):405–409.
   PubMed Web of Science ®Google Scholar
• Hillis SD, Marchbanks PA, Peterson HB. The effectiveness of hysterectomy for chronic pelvic pain. Obstet Gynecol. 1995;86(6):941–945.
   PubMed Web of Science ®Google Scholar
• van Reijn-Baggen DA, Han-Geurts IJM, Voorham-van der Zalm PJ, et al. Pelvic floor physical therapy for pelvic floor hypertonicity: a systematic review of treatment efficacy. Sex Med Rev. 2022;10(2):209–230.
   PubMed Web of Science ®Google Scholar
• Grinberg K, Sela Y, Nissanholtz-Gannot R. New insights about Chronic Pelvic Pain Syndrome (CPPS). IJERPH. 2020;17(9):3005.
   Web of Science ®Google Scholar